DIRECT Trial - interferon alfacon-1 plus ribavirin DIRECT is a randomized, open-label, phase III investigational research study that will evaluate the safety and efficacy of daily administration of subcutaneous interferon alfacon-1 plus ribavirin versus no treatment in HCV patients who have not responded to previous combination therapy with pegylated interferon alfa plus ribavirin. Directtrial.com~Site InfoWhoisTrace RouteRBL Check
InterMune: Home InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary disease, infectious disease and cancer.
Intermune.com~Site InfoWhoisTrace RouteRBL Check